Literature DB >> 30003344

Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine.

Minjee Kim1, Sani H Kizilbash2, Janice K Laramy1, Gautham Gampa1, Karen E Parrish1, Jann N Sarkaria2, William F Elmquist3.   

Abstract

The treatment of metastatic lesions in the brain represents a serious unmet medical need in the field of neuro-oncology. Even though many effective compounds have demonstrated success in treating peripheral (non-CNS) tumors with targeted agents, one aspect of this lack of success in the brain may be related to poor delivery of otherwise effective compounds. Many factors can influence the brain delivery of these agents, but one key barrier is a heterogeneously "leaky" BBB that expresses efflux transporters that limit the BBB permeability for many targeted agents. Future success in therapeutics for brain metastases must take into account the adequate delivery of "active, free drug" to the target, and may include combinations of targeted drugs that are appropriate to address each individual patient's tumor type. This review discusses some issues that are pertinent to precision medicine for brain metastases, using specific examples of tumor types that have a high incidence of brain metastases.

Entities:  

Keywords:  blood-brain barrier; brain metastases; drug delivery; efflux transporters; metastasize; molecularly-targeted anti-cancer agents

Mesh：

Substances：

Year:  2018        PMID： 30003344      PMCID： PMC6700736          DOI： 10.1007/s11095-018-2455-9

Source DB:  PubMed          Journal:  Pharm Res        ISSN： 0724-8741            Impact factor:   4.200


  200 in total

1.  Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group.

Authors:  A Aupérin; R Arriagada; J P Pignon; C Le Péchoux; A Gregor; R J Stephens; P E Kristjansen; B E Johnson; H Ueoka; H Wagner; J Aisner
Journal:  N Engl J Med       Date:  1999-08-12       Impact factor: 91.245

2.  Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma.

Authors:  Olivier Bailon; Kader Chouahnia; Alexandre Augier; Thierry Bouillet; Ségolène Billot; Irène Coman; Rénata Ursu; Catherine Belin; Laurent Zelek; Gaëtan Des Guetz; Christine Levy; Antoine F Carpentier; Jean-François Morere
Journal:  Neuro Oncol       Date:  2012-02-22       Impact factor: 12.300

3.  Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors.

Authors:  Arkadiusz Z Dudek; Ahmad Raza; Ming Chi; Meghali Singhal; Rajneet Oberoi; Rajendar K Mittapalli; Sagar Agarwal; William F Elmquist
Journal:  Clin Genitourin Cancer       Date:  2012-12-21       Impact factor: 2.872

4.  Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain.

Authors:  Rajneet K Oberoi; Rajendar K Mittapalli; William F Elmquist
Journal:  J Pharmacol Exp Ther       Date:  2013-10-10       Impact factor: 4.030

Review 5.  Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer.

Authors:  Timothy P Heffron
Journal:  J Med Chem       Date:  2016-08-03       Impact factor: 7.446

6.  Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study.

Authors:  Minesh P Mehta; Ding Wang; Fen Wang; Lawrence Kleinberg; Anthony Brade; H Ian Robins; Aruna Turaka; Terri Leahy; Diane Medina; Hao Xiong; Nael M Mostafa; Martin Dunbar; Ming Zhu; Jane Qian; Kyle Holen; Vincent Giranda; Walter J Curran
Journal:  J Neurooncol       Date:  2015-02-15       Impact factor: 4.130

Review 7.  Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm.

Authors:  Elizabeth R Gerstner; Robert L Fine
Journal:  J Clin Oncol       Date:  2007-06-01       Impact factor: 44.544

8.  Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

Authors:  Georgina V Long; Jeffrey S Weber; Jeffrey R Infante; Kevin B Kim; Adil Daud; Rene Gonzalez; Jeffrey A Sosman; Omid Hamid; Lynn Schuchter; Jonathan Cebon; Richard F Kefford; Donald Lawrence; Ragini Kudchadkar; Howard A Burris; Gerald S Falchook; Alain Algazi; Karl Lewis; Igor Puzanov; Nageatte Ibrahim; Peng Sun; Elizabeth Cunningham; Amy S Kline; Heather Del Buono; Diane Opatt McDowell; Kiran Patel; Keith T Flaherty
Journal:  J Clin Oncol       Date:  2016-01-25       Impact factor: 44.544

9.  PARP Inhibitors as P-glyoprotein Substrates.

Authors:  Denise Lawlor; Patricia Martin; Steven Busschots; Julien Thery; John J O'Leary; Bryan T Hennessy; Britta Stordal
Journal:  J Pharm Sci       Date:  2014-04-03       Impact factor: 3.534

10.  P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.

Authors:  Ryohei Katayama; Takuya Sakashita; Noriko Yanagitani; Hironori Ninomiya; Atsushi Horiike; Luc Friboulet; Justin F Gainor; Noriko Motoi; Akito Dobashi; Seiji Sakata; Yuichi Tambo; Satoru Kitazono; Shigeo Sato; Sumie Koike; A John Iafrate; Mari Mino-Kenudson; Yuichi Ishikawa; Alice T Shaw; Jeffrey A Engelman; Kengo Takeuchi; Makoto Nishio; Naoya Fujita
Journal:  EBioMedicine       Date:  2015-12-12       Impact factor: 8.143
View more
  21 in total

1.  Brain Distributional Kinetics of a Novel MDM2 Inhibitor SAR405838: Implications for Use in Brain Tumor Therapy.

Authors:  Minjee Kim; Janice K Laramy; Gautham Gampa; Karen E Parrish; Richard Brundage; Jann N Sarkaria; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2019-10-16       Impact factor: 3.922

2.  Does an optimal management of brain metastases from oncogenic-driver non-small cell lung cancer exist?

Authors:  Roberta Rudà; Riccardo Soffietti
Journal:  Neuro Oncol       Date:  2020-02-20       Impact factor: 12.300

Review 3.  The blood-brain barrier and blood-tumour barrier in brain tumours and metastases.

Authors:  Costas D Arvanitis; Gino B Ferraro; Rakesh K Jain
Journal:  Nat Rev Cancer       Date:  2019-10-10       Impact factor: 60.716

4.  Pharmacological Optimization for Successful Traumatic Brain Injury Drug Development.

Authors:  Samuel M Poloyac; Richard J Bertz; Lee A McDermott; Punit Marathe
Journal:  J Neurotrauma       Date:  2019-04-10       Impact factor: 5.269

5.  Central Nervous System Delivery of the Catalytic Subunit of DNA-Dependent Protein Kinase Inhibitor Peposertib as Radiosensitizer for Brain Metastases.

Authors:  Surabhi Talele; Wenjuan Zhang; Ju-Hee Oh; Danielle M Burgenske; Ann C Mladek; Sonja Dragojevic; Jann N Sarkaria; William F Elmquist
Journal:  J Pharmacol Exp Ther       Date:  2022-04-03       Impact factor: 4.402

6.  In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling.

Authors:  William F Elmquist; Jann N Sarkaria; Sani H Kizilbash; Shiv K Gupta; Karen E Parrish; Janice K Laramy; Minjee Kim; Gautham Gampa; Brett L Carlson; Katrina K Bakken; Ann C Mladek; Mark A Schroeder; Paul A Decker
Journal:  Mol Cancer Ther       Date:  2021-03-30       Impact factor: 6.261

Review 7.  Deciphering molecular mechanisms of metastasis: novel insights into targets and therapeutics.

Authors:  Bikashita Kalita; Mohane Selvaraj Coumar
Journal:  Cell Oncol (Dordr)       Date:  2021-04-29       Impact factor: 6.730

Review 8.  Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology.

Authors:  Benjamin B Kasten; Neha Udayakumar; Jianmei W Leavenworth; Anna M Wu; Suzanne E Lapi; Jonathan E McConathy; Anna G Sorace; Asim K Bag; James M Markert; Jason M Warram
Journal:  Theranostics       Date:  2019-07-09       Impact factor: 11.556

9.  ATP-binding cassette transporters restrict drug delivery and efficacy against brain tumors even when blood-brain barrier integrity is lost.

Authors:  Mark C de Gooijer; E Marleen Kemper; Levi C M Buil; Ceren H Çitirikkaya; Tessa Buckle; Jos H Beijnen; Olaf van Tellingen
Journal:  Cell Rep Med       Date:  2021-01-19

Review 10.  Management of brain metastases according to molecular subtypes.

Authors:  Riccardo Soffietti; Manmeet Ahluwalia; Nancy Lin; Roberta Rudà
Journal:  Nat Rev Neurol       Date:  2020-09-01       Impact factor: 42.937
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.